Literature DB >> 3431552

Generation of complement anaphylatoxins and C5b-9 by crystalline cholesterol oxidation derivatives depends on hydroxyl group number and position.

P S Seifert1, M D Kazatchkine.   

Abstract

Cholesterol crystals activate the human alternative complement pathway. Loss of Factor B hemolytic activity in C2-deficient serum was comparable to that in normal human serum after incubation with cholesterol crystals. Consumption of Factor B hemolytic activity in normal serum incubated with cholesterol occurred in a time- and dose-dependent manner. The reduced capacity of crystals-absorbed serum to activate C2, but not Factor B, on fresh crystals, indicated that cholesterol mediates antibody-dependent classical pathway activation in addition to alternative pathway activation in whole serum. Cholestane triol, an oxidation derivative of cholesterol which bears three hydroxyl groups, cleaved 5-fold more C3 than cholesterol in normal human serum. Three cholesterol derivatives, each bearing two hydroxyl groups, were intermediate activators between cholesterol and cholestane triol. The compounds differed, however, in their complement-activating ability, indicating that hydroxyl position as well as number exerts an influence on complement activation. Measurements of C3adesArg and C5adesArg antigens in cholesterol crystal treated serum revealed that approx. 10% of total serum C3 was cleaved and that, on a molar basis, only 3% C5 cleavage occurred relative to C3 cleavage. For 1 mole of C5a generated, 0.1 moles of fluid-phase C5b-9 was detected. Although the extent of C3 cleavage varied with each cholesterol derivative depending on the position and number of hydroxyl groups, the relative coupling efficiency of C3 and C5 cleavage and C5a and C5b-9 generation was similar for all compounds. The ability of cholesterol and its oxidation products to generate anaphylatoxins and C5b-9 complexes may be of importance in mediating inflammatory processes involved in atherogenesis.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3431552     DOI: 10.1016/0161-5890(87)90125-8

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  15 in total

Review 1.  Complementing the inflammasome.

Authors:  Martha Triantafilou; Timothy R Hughes; Bryan Paul Morgan; Kathy Triantafilou
Journal:  Immunology       Date:  2016-02       Impact factor: 7.397

Review 2.  Review of progress in sterol oxidations: 1987-1995.

Authors:  L L Smith
Journal:  Lipids       Date:  1996-05       Impact factor: 1.880

3.  Plasma factor triggering alternative complement pathway activation by liposomes.

Authors:  K Funato; C Yamashita; J Kamada; S Tominaga; H Kiwada
Journal:  Pharm Res       Date:  1994-03       Impact factor: 4.200

4.  Decay-accelerating factor is expressed on vascular smooth muscle cells in human atherosclerotic lesions.

Authors:  P S Seifert; G K Hansson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

5.  Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release.

Authors:  Eivind O Samstad; Nathalie Niyonzima; Stig Nymo; Marie H Aune; Liv Ryan; Siril S Bakke; Knut T Lappegård; Ole-Lars Brekke; John D Lambris; Jan K Damås; Eicke Latz; Tom E Mollnes; Terje Espevik
Journal:  J Immunol       Date:  2014-02-19       Impact factor: 5.422

Review 6.  The role of complement activation in atherosclerosis.

Authors:  Florin Niculescu; Horea Rus
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

Review 7.  Vaccination and atherosclerosis.

Authors:  Xinghua Zhou; Göran K Hansson
Journal:  Curr Atheroscler Rep       Date:  2004-03       Impact factor: 5.113

8.  Studies on the immunological properties of oxysterols: in vivo actions of 7,25-dihydroxycholesterol upon murine peritoneal cells.

Authors:  C Moog; Y H Ji; C Waltzinger; B Luu; P Bischoff
Journal:  Immunology       Date:  1990-07       Impact factor: 7.397

9.  Decay-accelerating factor suppresses complement C3 activation and retards atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Viola W Y Leung; Sheng Yun; Marina Botto; Justin C Mason; Talat H Malik; Wenchao Song; Danielle Paixao-Cavalcante; Matthew C Pickering; Joseph J Boyle; Dorian O Haskard
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

10.  ABCA1 (ATP-Binding Cassette Transporter A1) Mediates ApoA-I (Apolipoprotein A-I) and ApoA-I Mimetic Peptide Mobilization of Extracellular Cholesterol Microdomains Deposited by Macrophages.

Authors:  Xueting Jin; Denis Sviridov; Ying Liu; Boris Vaisman; Lia Addadi; Alan T Remaley; Howard S Kruth
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-10-06       Impact factor: 8.311

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.